Resources in Our Area

Children's Hospital

Children's Hospital - (Directions)
13123 East 16th Avenue
Aurora, CO 80045

Meets: Meets every other month

Contact Hallie Johannisson for more information.

Phone: 720-777-6669

A Multi-center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficiency of Rifaximin 550 mg BID for 6 months in Preventing Hepat

University of Colorado Health Sciences Center
Denver, CO

Drug being used: Rifaximin vs placebo
Type of patients being enrolled: At least two episodes of hepatic encephalopathy in the last 6 months
Randomization ratio: 1:1
Treatment period: 6 months
Follow-up period: Non, possible opportunity for open-label study
Physician: Lisa Forman, M.D.

Contact Anastasia Krojec, RN for more information.

Phone: (303) 315-0985

A multicenter, randomized, open-label, parallel-group study of Infergen/Ribavirin in Patients with Chronic Hepatitis C Virus Who are Partial Responder

Arapahoe Gastroenterology/Rocky Mountain Clinical Research
Denver, CO

Drug being used: Patients will be randomized to Infergen/Ribavirin or Peginterferon alfa-2a or 2b by weekly subcutaneous injection.
Type of patients being enrolled: Geno type 1 currently in therapy with a documented partial response at 4 and 12 weeks of therapy
Randomization ratio: 2:1 Infergen vs Peginterferon alfa-2a or alfa 2b
Treatment period: Infergen will be for an additional 24 or 36 weeks after 12 weeks of therapy
Follow-up period: 24 weeks
Physician: Andrej Triebling, MD, PhD

Contact Marylyn Baker, CCRC for more information.

Phone: (303) 279-1550

Achieve 2/3

University of Colorado Health Sciences Center
Denver, CO

Drug being used: Alb Interferon vs. Peg Interferon
Type of patients being enrolled: Geno 2/3 Naïve with compensated liver disease
Randomization ratio: 1:1:1
Treatment period: 24 weeks
Follow-up period: 24 weeks
Physician: Gregory T. Everson, M.D.

Contact Jennifer DeSanto, RN for more information.

Phone: (303) 315-1128

Hepatitis C-Naïve/relapse/non-responder preferred

University of Colorado Health Sciences Center
Denver, CO

Drug being used: GI 5005 01
Type of Patients being enrolled: Non-cirrhotic, non-diabetic, all genotypes
Randomization ratio: Patient randomized 12:4
Treatment period: 1 year complete--7 total injections during the 12 week period with follow-up after injections completed.
Physician: Gregory T. Everson, M.D.

Contact Marlene Warren, RN for more information.

Phone: (303) 315-1135

Non-Responders/Relapsers

South Denver Gastroenterology
Denver, CO

Drug being used: Combination: Pegasys/Copegus/VX-950
Type of patients being enrolled: Partial Inclusions: Genotype 1; Diagnosis >6months prior to screen; Stable hematology; Min. Tx of 12 weeks with Peg-IFN/RBV. Partial Exclusions: Prior use of Protease Inhibitor for any duration; Significant Liver Disease in Addition to Hepatitis C; Drug/Alcohol Abuse within 12 months
Physician: Marcelo Kuglemas, MD

Contact Lisa Montgomery, BA CRC for more information.

Phone: (303) 406-4139

Non-Responders/Relapsers

South Denver Gastroenterology
Denver, CO

Drug being used: Combination: Pegasys/Copegus/Polymerase Inhibitor
Type of patients being enrolled: Partial Inclusions: Genotype 1; Liver Biopsy within 24 months: Cirrohsis may be allowed; Compensated Liver Disease (Child-Pugh Grade A clinical classification only). Partial Exclusions: Platelet count <90,000; ANC <1500; Hgb <13; History of severe psychiatric disease, including psychosis and/or depression requiring hospitalization; Alcohol/drug abuse within 12 months of study participation
Physician: Marcelo Kuglemas, MD

Contact Lisa Montgomery, BA CRC for more information.

Phone: (303) 406-4139

Novartis Proof of Concept Study - Phase I study of a cyclosporine analog, NIM811, to determine the safety and tolerability and pharmacokinetics

Rocky Mountain Gastroenterology Associates/Rocky Mountain Clinical Research
Denver, CO

Drug being used: NIM811
Type of patients being enrolled: Hepatitis C - Genotype 1
Treatment period: 14 days
Follow-up period: 28 days
Physician: John S. Goff, MD

Contact Gail Danhour, RN, CCRC for more information.

Phone: (303) 279-1550

Peach Study

University of Colorado Health Sciences Center

Drug being used: R05024048, Phase 1
Type of patients being enrolled: Genotype 1, Relapser or non-responder on no medication, healthy
Randomization ratio: 3:1
Treatment period: 2 weeks
Follow-up period: 2 weeks
Physician: Gregory T. Everson, M.D.

Contact Andrea Herman, RN for more information.

Phone: (303) 3154-6827

Phase 2 study of Chronic Hepatitis B Decompensated liver disease

University of Colorado Health Sciences Center
Denver, CO

Drug being used: Comparing Tenofovir, Emtricitabine and Entecavir
Type of patients being enrolled: Chronic Hepatitis B with Decompensated liver disease and a CPT score of 7-12
Randomization ratio: 2:2:1
Treatments period: 96 weeks
Physician: Gregory T. Everson, M.D.

Contact Marlene Warren, RN for more information.

Phone: (303) 315-1135

Progress Study for Patients with High Body Weight

University of Colorado Health Sciences Center
Denver, CO

Drug being used: High induction doses of Pegasys/Ribavirin
Type of patients being enrolled: High body weight > 85 kg, Geno 1, Naive
Randomization ratio: 1:1:2:2
Treatment period: 48 weeks
Follow-up period: 24 weeks
Physician: Gregory T. Everson, M.D.

Contact Jennifer DeSanto, RN for more information.

Phone: (303) 315-1128

Satavaptan Cirrhotic Ascites Treatment Study (CATS)

University of Colorado Health Sciences Center
Denver, CO

Drug being used: Satavaptan vs. placebo
Type of patients being enrolled: Patients with history of cirrhotic ascites, but having had no more than one therapeutic paracentesis in the last 6 months
Randomization ratio: 1:1
Treatment period: Up to 1 year
Follow-up period: none
Physician: James Trotter, M.D.

Contact Ted Perry for more information.

Phone: (303) 315-0528

Study to Assess The Safety and Effectiveness of PYN17(a combination of Chinese and European medicinal herbs) in treatment of Fatigue and Compromised Q

Arapahoe Gastroenterology/Rocky Mountain Clinical Research
Denver, CO

Drug being used: PYN17
Type of patients being enrolled: Geno type 1, Confirmed Biopsy within 2 years
May have failed or never received standard therapy
Treatment period: 4 weeks
Follow-up period: 4 weeks
Physician: Bahri Bilir, MD

Contact Marylyn Baker, CCRC for more information.

Phone: (303) 279-1550

Study to Assess The Safety and Effectiveness of PYN17(a combination of Chinese and European medicinal herbs) in treatment of Fatigue and Compromised Q

Rocky Mountain Gastroenterology Associates/Rocky Mountain Clinical Research
Denver, CO

Drug being used: PYN17
Type of patients being enrolled: Geno type 1, Confirmed Biopsy within 2 years. May have failed or never received standard therapy
Treatment period: 4 weeks
Follow-up period: 4 weeks
Physician: John S. Goff, MD

Contact Gail Danhour, RN, CCRC for more information.

Phone: (303) 279-1550

Treatment Naïve

South Denver Gastroenterology
Denver, CO

Drug being used: Open-Label Study: Albuferon Interferon Alfa-2b in Combination with Ribavirin Compared to Peginterferon Alfa-2a in Combination with Ribavirin
Type of patients being enrolled: Partial Inclusions: Genotype 1; Treatment Naïve; Stable hematology; AFP <20 ng/ml. Partial Exclusions: History of moderate, severe, or uncontrolled psychiatric disease- especially depression; Drug or Alcohol abuse within 6 months of study participation; A positive alcohol or drug screen at the start of study
Physician: Marcelo Kuglemas, MD

Contact Lisa Montgomery, BA CRC for more information.

Phone: (303) 406-4139

Treatment Naïve

South Denver Gastroenterology
Denver, CO

Drug being used: Elevated doses of Pegasys and Copegus in Patients with a High Viral Titer and Baseline Body Weight of Greater than or Equal to 85kg
Type of patients being enrolled: Partial Inclusions: Genotype 1; Body Weight >85kg; HCV RNA > 400,000 IU/ml; Liver biopsy within two years; cirrhosis maybe accepted. Partial Exclusions: Previous treatment with Interferon, ribavirin, investigational protease or polymerase inhibitor drugs for any length of time; ANC < 1500; Plt count , 90,000; Severe psychiatric disease including depression resulting in hospitalization.
Physician: Marcelo Kuglemas, MD

Contact Lisa Montgomery, BA CRC for more information.

Phone: (303) 406-4139

Donor Alliance

In cooperation with others, Donor Alliance facilitates the donation and recovery of organs and tissues for people needing transplantation.

Phone: (888) 868-4747
Web: www.donoralliance.org

Donor Awareness Council

The Donor Awareness Council conducts public education programs, advocates for public policy to increase donation, and works in partnership with the Colorado and Wyoming Driver License Office programs.

Phone: (888) 388-8605
Web: www.donor-awareness.org

Laboratories at Bonfils/Bonfils Blood Center

In partnership with the community, Bonfils Blood Center saves and enhances lives. Bonfils Blood Center maintains the vision held by its founders of maintaining a safe, adequate and efficiently produced blood supply for the community.

Phone: (800) 365-0006
Web: www.bonfils.org

Organ Procurement and Transplantation Network

The Organ Procurement and Transplantation Network (OPTN) is the unified transplant network established by the United States Congress under the National Organ Transplant Act (NOTA) of 1984. OPTN maintains the only national patient waiting list and features the most comprehensive data available in any single field of medicine.

Phone: (888) TX-INFO-1
Web: www.optn.org

Transplant Recipient International Organization

TRIO is an independent, not-for-profit, international organization committed to improving the quality of life of transplant candidates, recipients, their families and the families of organ and tissue donors.

Phone: (800) TRIO-386
Web: www.trioweb.org

United Network for Organ Sharing (UNOS)

Located in Richmond, Virginia, the United Network for Organ Sharing (UNOS) is a non-profit, scientific and educational organization that administers the nation's only Organ Procurement and Transplantation Network (OPTN) established by the U.S. Congress in 1984. The mission is to advance organ availability and transplantation by uniting and supporting our communities for the benefit of patients through education, technology and policy development.

Phone: (888) 894-6361
Web: www.unos.org

Center for Disease Control and Prevention (CDC)

The Center for Disease Control (CDC) is one of the major operating components of the Department of Health & Human Services. The mission of the CDC is to promote health and quality of life by preventing and controlling disease, injury or disability.

Phone: (800) CDC-INFO
Web: www.cdc.gov/ncidod/diseases/hepatitis/

Children’s Liver Disease Foundation

The mission of Children's Liver Disease Foundation is to fight childhood liver disease through funding pioneering medical research, providing effective education and giving professional and caring support to families and young people with liver disease.

Phone: 44 (0) 121 212 3839
Web: www.childliverdisease.org

Directory of Digestive Disease Organizations for Patients

This directory lists voluntary and private organizations involved in digestive diseases-related activities for patients. The organizations offer educational materials and other services.

Phone: 503–885–6455
Web: digestive.niddk.nih.gov/resources/patient.htm

Hepatitis Foundation International

The Hepatitis Foundation International (HFI) is dedicated to the eradication of viral hepatitis, a disease affecting over 500 million people around the world. We seek to raise awareness of this enormous worldwide problem and to motivate people to support this important – and winnable – battle.

Phone: (800) 891-0707
Web: www.hepfi.org

National Institute of Allergy and Infectious Diseases

The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases.

Phone: (301) 496-5717
Web: www.niaid.nih.gov

National Institute of Diabetes & Digestive & Kidney Diseases

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) conducts and supports research on many of the most serious diseases affecting public health. The institute supports much of the clinical research on the diseases of internal medicine and related subspecialty fields as well as many basic science disciplines.

Phone: (866) 319-4357
Web: www.niddk.nih.gov

National Institute of Health (NIH)

The NIH mission is to uncover new knowledge that will lead to better health for everyone. NIH works toward that mission by: conducting research in its own laboratories; supporting the research of non-Federal scientists in universities, medical schools, hospitals, and research institutions throughout the country and abroad; helping in the training of research investigators; and fostering communication of medical and health sciences information.

Phone: (301) 496-4000
Web: www.nih.gov

PBCers Organization

The mission of PBCers Organization is to unite people with Primary Biliary Cirrhosis, help them cope with their disease and improve the quality of their lives through support and education using an online medium.

Web: www.pbcers.com

The Hep C Connection

Hep C Connection is an education, support, and prevention network for those affected by, or at risk for, hepatitis C. Hep C Connection is one of the nation’s premier hepatitis C-focused advocacy organizations and the only one of its kind in Colorado. We have a proven history of community education, patient support, and disease prevention strategies.

Phone: (800) 390-1202
Web: www.hepc-connection.org

The Hepatitis B Foundation

The Hepatitis B Foundation is dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide. Their commitment includes funding focused research, promoting disease awareness, supporting immunization and treatment initiatives, and serving as the primary source of information for patients and their families, the medical and scientific community, and the general public.

Phone: (215) 489-4900
Web: www.hepb.org